APA (7th ed.) Citation

Fu, C., Yan, L., Yao, W., Shang, J., Jin, S., Yan, S., . . . Li, Z. (2024). A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma. Blood, 144(Supplement 1), 4843. https://doi.org/10.1182/blood-2024-204401

Chicago Style (17th ed.) Citation

Fu, Chengcheng, et al. "A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma." Blood 144, no. Supplement 1 (2024): 4843. https://doi.org/10.1182/blood-2024-204401.

MLA (9th ed.) Citation

Fu, Chengcheng, et al. "A First-in-Human Study of CT0590, a Triple Knock-out, Allogeneic CAR T-Cell Therapy Targeting BCMA and NKG2A, in Subjects with Relapsed/Refractory Multiple Myeloma." Blood, vol. 144, no. Supplement 1, 2024, p. 4843, https://doi.org/10.1182/blood-2024-204401.